Premium
P2‐059: PHOTOOXYGENATION BY BIOCOMPATIBLE CATALYST REDUCES THE Aβ LEVEL IN THE BRAINS OF ALZHEIMER DISEASE MODEL MICE
Author(s) -
Tomita Taisuke,
Ozawa Shuta,
Sohma Youhei,
Kanai Motomu,
Hori Yukiko
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.2466
Subject(s) - photooxygenation , catalysis , neurotoxicity , chemistry , hippocampus , pathogenesis , peptide , in vivo , biophysics , photochemistry , biochemistry , oxygen , biology , immunology , endocrinology , singlet oxygen , toxicity , organic chemistry , genetics
of AD progression. Daily drug/vehicle treatment began at 2 months of age. Stress for the 6 and 12 month groups started at 2 and 6 months, respectively. Results:Overall, treated PSAPPmice resulted in significant reduction of Ab levels, plaque accumulation, and improved hippocampus-dependent memory performance relative to the controls. This study suggests that CRFR1 antagonist treatment provides a potential preventative and disease-modifying therapy for populations exposed to stress and at risk for AD development. Conclusions: Our data provides an important relationship between stress signaling in the CNS and the neuropathology of AD.